• Home | Global Data CRO
  • Our Company
    • About Us
    • Executive Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Global Leaders
    • Working with MMS
    • Certifications
  • Services
    • Regulatory Affairs
      • Regulatory Affairs Services
      • Regulatory Strategy Consulting
      • Regulatory Affairs Management
      • Regulatory Operations
    • Data Management and Biostatistics
    • Regulatory and Medical Writing
    • Transparency Services
      • Transparency and Disclosure Services
      • REGISTRATION AND RESULTS DISCLOSURES
      • DATA AND DOCUMENT ANONYMIZATION
      • LAY SUMMARIES
    • Quality and Compliance services
    • Drug Safety and Pharmacovigilance
    • Rare Disease
    • Quality Control Services
    • Project Advisory Services
    • Data Science
  • Technology
    • Datacise
    • Automatiqc
    • PVantage
    • Technology Implementation
    • SmartStart Document Templates
  • Functional Services (FSP)
  • Webinars
  • News and Media
  • MMS Blog
  • Careers
    • MMS Careers
    • Opportunities
    • MMS Experience
    • MMS Culture
    • Global Benefits
    • FAQ
  • Learning
  • Contact Us
MMS Holdings
How to Maximize FSP Partnerships – Scalability, Innovation, and Efficiencies

How to Maximize FSP Partnerships – Scalability, Innovation, and Efficiencies

by Prakash Achaary | Jul 20, 2021 | Blog

FSP partnership models, when developed to find the right level of oversight, scale, pricing, and governance to meet a Sponsor’s needs, offer a functional provider solution that can benefit an organization in a rapidly evolving pharmaceutical industry. For example, The...

Recent Posts

  • MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise
  • New FDA Policies and Procedures for Products Submitted Under Accelerated Pathways : Understanding CDER MAPP 5015.13
  • 10 Things to Consider When Discussing and Planning a Decentralized Clinical Trial (DCT)
  • SENDing Successful Nonclinical Submissions through Validation, Review, and Beyond
  • Orphan Drug Designations in the EU: Recent Rare Disease Treatment Updates

Tags

biostatistics Careers clinical research clinical study reports clinical trial disclosure clinical trials clinical trial transparency Compliance conference COVID-19 CRO data management data privacy data science decentralized clinical trials diversity and inclusion drug development eCOA & ePro EMA FDA Functional Service Provider (FSP) GXP auditing Health Analytics Collective innovation Lay summaries leadership medical writing MMS Academy NDA submission News Orphan Drug Designation Applications PDUFA VII pharmacovigilance PhUSE plain language summary Policy 0070 Praxis bioresearch quality and compliance quality control rare disease real world data regulatory affairs regulatory operations statistical programming transparency